Inicio>>Signaling Pathways>> Neuroscience>> 5-HT Receptor>>(4E)-SUN9221

(4E)-SUN9221

Catalog No.GC32644

(4E)-SUN9221 es un potente antagonista del receptor α1-adrenérgico y del receptor 5-HT2, con actividad antihipertensiva y antiagregaciÓn plaquetaria.

Products are for research use only. Not for human use. We do not sell to patients.

(4E)-SUN9221 Chemical Structure

Cas No.: 222318-55-0

Tamaño Precio Disponibilidad Cantidad
1mg
1.324,00 $
Disponible
5mg
2.979,00 $
Disponible
10mg
5.066,00 $
Disponible
20mg
8.935,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(4E)-SUN9221 is a potent antagonist of α1-adrenergic receptor and 5-HT2 receptor, with antihypertensive and anti-platelet aggregation activities.

(4E)-SUN9221 potently inhibits collagen-, ADP- and epinephrine-induced platelet aggregation, with IC50s of 10 nM, 35 nM, 14 nM, respectively, in human platelet-rich plasma (PRP). (4E)-SUN9221 displays potent α1-adrenergic antagonist activity (pA2 =8.89±0.21) and 5-HT2 antagonist activity (pA2 =8.74±0.22)[1].

(4E)-SUN9221 (1, 3, 10 mg/kg, p.o.) reduces the blood pressure in a dose-dependent manner in conscious spontaneously hypertensive rats (SHR). (4E)-SUN9221 (3 mg/kg) exhibits antihypertensive activity in SHR[1].

[1]. Mizuno A, et al. Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56.

Reseñas

Review for (4E)-SUN9221

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (4E)-SUN9221

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.